The OIE World Fund has worldwide experience in the management of vaccine banks and the delivery of vaccines for Avian Influenza (AI), Foot-and-Mouth Disease (FMD), Rabies (vaccination of dogs), and Peste des Petits Ruminants (PPR).
Vaccine banks ensure the procurement of high quality vaccines manufactured in line with OIE intergovernmental standards and delivered in a timely manner.
When quality vaccines are provided to developing countries at the airport of destination, the beneficiary country can concentrate its efforts and resources on implementing the vaccination campaigns (mobilisation of human, financial and technical resources, such as staff for vaccination, cold chain transport and storage, vaccination consumables, and follow-up on vaccination campaigns), or on contracting public/private partnerships with implementing partners such as NGOs, for instance.
The use of the vaccine bank mechanism encourages beneficiary countries to act and creates leverage effects when these countries decide to fund animal disease control programmes and implement them efficiently. Vaccine banks enable economies of scale, synergies and leveraging of results while contributing to harmonisation and coordination of global and regional control programmes. In addition, they allow for multi-party vaccination campaigns, public–private partnerships and the possible involvement of non-governmental organisations.
As of January 2022, two OIE vaccine banks are active and focus on Rabies and Peste des Petits Ruminants (PPR).
OIE vaccine banks are established through international calls for tender and selection procedures involving independent committees composed of international experts (OIE reference laboratories) and donor representatives.
They can be activated only upon request from the country, through the OIE Delegate who sends an official request to the Director General of the OIE.
OIE regional antigen/vaccine banks may include ready-to-use, formulated vaccines which can be delivered in a timely manner if urgent requests arise. Production can also be organised on demand with possible replenishment mechanisms in order to meet the needs of a variety of different orders. This mechanism enables the rapid supply of emergency stocks of vaccines to affected countries, as well as planned deliveries at a lower cost, in order to vaccinate targeted animal populations at risk and to eventually target eradication wherever possible.
To date, the creation of vaccine banks, as well as vaccines delivered afterwards, have been supported financially by Australia (FMD and Rabies), Canada (AI and Rabies), China (FMD), the European Union (AI, FMD and Rabies), France (Rabies and FMD), Germany (Rabies), Japan (Rabies), the Republic of Korea (FMD), New Zealand (FMD), the World Bank (PPR) and the Bill & Melinda Gates Foundation (PPR).
Generally, OIE vaccine bank contracts include possible clauses for direct purchase by beneficiary countries or by international organisations and partners.
Considering the efficiency of the OIE mechanism for procurement of vaccines, WHO decided in 2014 to place all of its orders for rabies vaccines for dogs through the OIE Rabies Vaccine Bank. This has enabled the delivery by WHO of 16.3 million doses of rabies vaccines, as of January 2022.
In 2006, the OIE set up a first regional vaccine bank of Avian Influenza vaccines in Africa funded under the European Union Pan African Programme for the Control of Epizootics (PACE) and in 2007 enlarged this vaccine bank to a global scale (opening it to Asian countries) thanks to Canadian funds.
Through these two financial supports, a total of 62,017 million H5N2 doses were delivered to the following countries: Mauritania, Senegal, Egypt, Mauritius, Ghana, Togo and Vietnam. Egypt and Vietnam accounted for the most significant levels of distribution, with 28 million and 26.7 million doses respectively (including in kind donations of vaccines from the United Kingdom and Canada). The Avian Influenza vaccine bank is now closed.
The European Union funded Regional Cooperation Programme on Highly Pathogenic Emerging and Re-emerging animal diseases (HPED), that had commenced in 2010, has seen the expansion of the OIE’s vaccine bank concept to other diseases, adding Foot-and-Mouth Disease (FMD) and rabies (vaccination of dogs) in Asian countries. The initial target was to rapidly (emergency) provide eligible countries with a stock of vaccines to vaccinate animal populations at risk under the framework of agreed vaccination. This is how were created the OIE vaccine bank for FMD in 2011 and the Rabies vaccine bank in 2012.
The antigens reserved for FMD are mainly designed to be used for strategic vaccination in buffer zones (ring vaccination) and hot spots around disease-free areas in order to stop the spread of the disease, as well as to reduce the associated economic costs caused by the loss of FMD free status. Besides the European Union, additional financial support has been received from Australia, China, New Zealand and the Republic of Korea for the procurement of FMD vaccines to eligible countries. This has demonstrated the multi-donor approach supporting the concept of regional vaccine banks. The FMD antigen bank is now closed.
With reference to rabies, the OIE vaccine bank supports the delivery of injectable rabies vaccines for dogs to eligible countries. The elimination of rabies is both a public health and economic priority and, hence, preventing the spread of this zoonotic disease is essential in order to reduce the number of human deaths and the socio-economic cost of the post contamination treatment of humans. Dog vaccination against rabies is the only way to break the cycle of transmission among dogs and between dogs and humans. After Asia, the OIE Rabies vaccine bank was opened to eligible countries in Africa, with additional financial supports from France, Germany and the European Union.
In 2013, a PPR vaccine bank for Africa was established for the provision of high quality PPR vaccines to eligible African countries. Funding support for the PPR vaccine bank for Africa was provided by the Bill & Melinda Gates Foundation. This vaccine bank not only ensures the timely supply of high quality vaccines complying with international standards, but also facilitates the harmonisation of PPR control methods in Africa. The World Bank has also provided support to the OIE PPR vaccine bank for Africa through the Regional Sahel Pastoralism Support Project (PRAPS) which targets 6 countries in Western and Central Africa.
Number of doses delivered or ordered as of December 2021
|Vaccine type||Number of dosesdelivered or ordered|
|Rabies||Over 26.1 million doses to eligible countries in Africa and Asia*|
|FMD||Over 8.1 million doses to eligible countries in Asia**|
|PPR||Over 84.6 million doses to eligible countries in Africa|
* A delivery of 100 000 doses to Haiti was exceptionally made thanks to Canadian funds.
** A delivery of 500 000 doses to Algeria was exceptionally made thanks to World Bank funds.
- OIE Policy Paper on Vaccine Banks (October 2018)
- Interview of Dr Monique Eloit, Director General of the OIE, on the OIE Rabies vaccine bank
- Video on the OIE Rabies vaccine bank
- Infographics on the mechanism of the OIE vaccine banks
- Brochure on the OIE Rabies vaccine bank
- Infographics on deliveries of rabies vaccines